Skip to content

Join The Lazy Contractor's Blueprint live on Nov 28 — show up and get 1,000 free Mindy creditsJoin The Lazy Contractor's Blueprint, free and live on Nov 28

Register free
Home/Contractors/Basilea Pharmaceutica Ag/contracts

Federal Contractor Profile

Basilea Pharmaceutica Ag

$254M obligated·4 awards·1 agencies·2 NAICS
OverviewContractsAgenciesNAICS

Federal Contracts

Showing award actions 1–15 of 15 funded award actions, most recent first.

Contracts with positive obligations
4
Funded award actions shown
15
Obligations shown
$254M
Awarding agencies
1

This table shows award actions with a positive obligation. Zero-dollar and negative-dollar actions, such as administrative changes and deobligations, are not displayed. Multiple award actions may belong to the same contract.

Award data as of November 2, 2026. Source: USAspending federal award records.

DateAgencyPIIDNAICSDescriptionAmount
Aug 4, 2026Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA75A50123C00050541714VENATORX PHARMACEUTICALS: NEW ANTIBIOTICS TO TREAT DRUG-RESISTANT GRAM-NEGATIVE BACTERIA INCLUDING PUBLIC HEALTH PATHOGENS.$5.4M
Jul 28, 2026Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA75A50124C00033541714THE DEVELOPMENT OF ANTIMICROBIALS FOR THE TREATMENT OF RESISTANT FUNGAL AND BACTERIAL INFECTIONS - OTA$30M
May 27, 2026Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA75A50123C00050541714VENATORX PHARMACEUTICALS: NEW ANTIBIOTICS TO TREAT DRUG-RESISTANT GRAM-NEGATIVE BACTERIA INCLUDING PUBLIC HEALTH PATHOGENS.$13M
Feb 24, 2026Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA75A50123C00050541714VENATORX PHARMACEUTICALS: NEW ANTIBIOTICS TO TREAT DRUG-RESISTANT GRAM-NEGATIVE BACTERIA INCLUDING PUBLIC HEALTH PATHOGENS.$6.1M
Sep 15, 2025Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA75A50124C00033541714THE DEVELOPMENT OF ANTIMICROBIALS FOR THE TREATMENT OF RESISTANT FUNGAL AND BACTERIAL INFECTIONS - OTA$25M
Jul 7, 2025Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA75A50124C00033541714THE DEVELOPMENT OF ANTIMICROBIALS FOR THE TREATMENT OF RESISTANT FUNGAL AND BACTERIAL INFECTIONS - OTA$39M
Sep 18, 2024Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA75A50124C00033541714THE DEVELOPMENT OF ANTIMICROBIALS FOR THE TREATMENT OF RESISTANT FUNGAL AND BACTERIAL INFECTIONS - OTA$29M
Sep 28, 2022Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMAHHSO100201600002C541711IGF::OT::IGF ADVANCED DEVELOPMENT OF CEFTOBIPROLE$3.2M
Aug 6, 2021Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMAHHSO100201600002C541711IGF::OT::IGF ADVANCED DEVELOPMENT OF CEFTOBIPROLE$4.3M
Sep 16, 2020Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMAHHSO100201600002C541711IGF::OT::IGF ADVANCED DEVELOPMENT OF CEFTOBIPROLE$1.5M
Sep 30, 2019Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMAHHSO100201600002C541711IGF::OT::IGF ADVANCED DEVELOPMENT OF CEFTOBIPROLE$8.0M
Sep 11, 2018Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMAHHSO100201600002C541711IGF::OT::IGF ADVANCED DEVELOPMENT OF CEFTOBIPROLE$10M
Feb 14, 2018Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMAHHSO100201600002C541711IGF::OT::IGF ADVANCED DEVELOPMENT OF CEFTOBIPROLE$10M
Jun 6, 2017Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMAHHSO100201600002C541711IGF::OT::IGF ADVANCED DEVELOPMENT OF CEFTOBIPROLE$55M
Apr 19, 2016Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMAHHSO100201600002C541711IGF::OT::IGF ADVANCED DEVELOPMENT OF CEFTOBIPROLE$20M

Get Alerted Before Basilea Pharmaceutica Ag's Next Recompete

Mindy monitors active contracts and flags recompetes 12 months out so you can position to compete.

Start for free